Asenapine News and Research

RSS
Asenapine is a new drug under development for the treatment of schizophrenia and acute mania associated with bipolar disorder.
Medicaid could save billions as patents for several blockbuster antipsychotic medications expire

Medicaid could save billions as patents for several blockbuster antipsychotic medications expire

Allergan announces U.S. availability of SAPHRIS 2.5 mg tablets for children with bipolar I disorder

Allergan announces U.S. availability of SAPHRIS 2.5 mg tablets for children with bipolar I disorder

Forest Laboratories third quarter net sales increase 24.9% to $846.8 million

Forest Laboratories third quarter net sales increase 24.9% to $846.8 million

Forest Laboratories to acquire exclusive rights in the U.S. for Saphris sublingual tablets

Forest Laboratories to acquire exclusive rights in the U.S. for Saphris sublingual tablets

Assurex Health announces release of new psychiatric pharmacogenomic test panel

Assurex Health announces release of new psychiatric pharmacogenomic test panel

New report finds little evidence to support off-label use of atypical antipsychotics

New report finds little evidence to support off-label use of atypical antipsychotics

Benefits and harms vary among atypical antipsychotics for off-label use

Benefits and harms vary among atypical antipsychotics for off-label use

Merck reports $342 million net income for 2010 third quarter

Merck reports $342 million net income for 2010 third quarter

Lundbeck, Merck announce commercialization agreement for SYCREST sublingual tablets

Lundbeck, Merck announce commercialization agreement for SYCREST sublingual tablets

European Commission approves MSD's MAA for SYCREST in manic episodes associated with bipolar I disorder

European Commission approves MSD's MAA for SYCREST in manic episodes associated with bipolar I disorder

Merck reports strong bottom-line performance in second quarter

Merck reports strong bottom-line performance in second quarter

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

Merck hosts R&D and Business Briefing

Merck hosts R&D and Business Briefing

Merck announces updated late-stage pipeline following its recent merger with Schering-Plough

Merck announces updated late-stage pipeline following its recent merger with Schering-Plough

Merck announces global sales of $27.4 billion for full-year 2009

Merck announces global sales of $27.4 billion for full-year 2009

Schering-Plough's Phase III study of Grass Allergy Immunotherapy meets primary endpoint

Schering-Plough's Phase III study of Grass Allergy Immunotherapy meets primary endpoint

Schering-Plough announces 2009 third quarter financial results

Schering-Plough announces 2009 third quarter financial results

Final results of SAPHRIS clinical study released

Final results of SAPHRIS clinical study released

Schering-Plough announces European filing of Sycrest (asenapine) for schizophrenia and bipolar I disorder

Schering-Plough announces European filing of Sycrest (asenapine) for schizophrenia and bipolar I disorder

Schering-Plough submits response to FDA for SAPHRIS (asenapine) in the acute treatment of schizophrenia and bipolar I disorder

Schering-Plough submits response to FDA for SAPHRIS (asenapine) in the acute treatment of schizophrenia and bipolar I disorder